Strikingly, a phase Ib/II study showed that napabucasin, a first-in-class cancer stemness inhibitor that targets the STAT3 pathway, when given with weekly paclitaxel treatments, has shown promising effects in metastatic TNBC patients who have progressed on taxane-based treatment regimens (Becerra et al., 2016). This evidence concerns the gene STAT3 and cancer.